Senseonics 8/8/2024 Earnings Report

Senseonics EPS Results

• Actual EPS: -$0.03
• Consensus EPS: -$0.03
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Senseonics Revenue Results

• Actual Revenue: $4.87 million
• Expected Revenue: $4.86 million
• Beat/Miss: Beat by +$10.00 thousand
• YoY Revenue Growth: N/A

Senseonics Announcement Details

• Date: 8/8/2024
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Senseonics (NYSE:SENS) is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe. The system pairs with a wearable transmitter and a mobile application, allowing users to track glucose trends, set alerts, and share data with clinicians. Senseonics supports ongoing research and development to expand its product portfolio and enhance sensor longevity and accuracy.

Senseonics holds regulatory approvals including FDA clearance in the United States and CE marking in the European Union, enabling commercialization across key global markets. The company has established partnerships with diabetes care providers and distributors throughout North America and Europe, with additional plans to extend its presence in regions such as the Middle East and Asia-Pacific. Under the leadership of President and Chief Executive Officer Timothy Goodnow, Senseonics continues to build its commercial footprint and pursue strategic collaborations to advance patient access to its long-term CGM technology.